阿奇霉素序贯疗法联合匹多莫德对支原体肺炎患儿血清炎性因子水平及免疫功能影响.docVIP

阿奇霉素序贯疗法联合匹多莫德对支原体肺炎患儿血清炎性因子水平及免疫功能影响 　　[摘要] 目的 探?阿奇霉素序贯疗法联合匹多莫德对支原体肺炎患儿血清炎性因子水平及免疫功能的影响。 方法 选择2016年1～12月来衡水市第四人民医院就诊的小儿支原体肺炎患儿147例。采用随机数字表法分为对照组和研究组，其中对照组患儿73例，研究组患儿74例。对照组采用单纯阿奇霉素序贯疗法治疗，研究组采用阿奇霉素序贯疗法联合匹多莫德治疗。比较两组患儿的血清炎性因子水平和免疫指标。 结果 研究组患儿的总有效率为95.95%，明显高于对照组（83.56%），差异有统计学意义（P 0.05）；治疗后，研究组患儿的血清肿瘤坏死因子[（0.72±0.14）mg/L]、白细胞介素-4[（25.14±2.54）ng/L]、白细胞介素-6[（7.43±2.42）ng/L]、白细胞介素-10[（26.73±2.49）ng/L]均明显低于对照组[（1.39±0.21）mg/L、（37.26±3.41）ng/L、（12.56±3.29）ng/L、（34.36±3.17）ng/L]，差异有统计学意义（P 0.05）；治疗后研究组患者的CD3+和CD4+均较治疗前有所上升，CD8+较治疗前明显降低，差异有统计学意义（P 0.05），且研究组改变的程度高于对照组，差异有统计学意义（P 0.05）。 结论 阿奇霉素序贯疗法联合匹多莫德具有良好的治疗效果，能够有效改善患者的炎性反应，提高患者的免疫功能，值得推广。 　　[关键词] 阿奇霉素；匹多莫德；支原体肺炎；血清炎性因子；免疫功能 　　[中图分类号] R725.6 [文献标识码] A [文章编号] 1673-7210（2018）01（b）-0132-04 　　[Abstract] Objective To investigate the effect of sequential treatment with Azithromycin combined with Pidotimod on the levels of serum inflammatory cytokines and immune function in children with Mycoplasma pneumonia. Methods The subjects of 147 children with Mycoplasma pneumonia in the Fourth Peoples Hospital of Hengshui from January 2016 to December 2016. Randomized divided into control group and research group， including 73 cases of children in the control group， 74 cases of study group. The control group was treated with Azithromycin sequential therapy. The control group was treated with Azithromycin sequential therapy. The study group was treated with Azithromycin sequential therapy combined with Pidotimod. Serum inflammatory factors and immune parameters were compared between the two groups. Results The total effective rate in the study group was 95.95%， which was significantly higher than that in the control group （83.56%） ， the difference was statistically significant （P 　　[Key words] Azithromycin； Pidotimod； Mycoplasma pneumonia； Serum inflammatory cytokines； Immune function 　　支原体肺炎是一种原发性非典型肺炎，主要由支原体（Mycoplasma pneumonia，MP）感染引起，在学龄前儿童中较为高发，占儿童社区获得性肺炎的10%～40%。其主要临床表现有顽固性剧烈咳嗽、肺炎支原体可引起扁桃体炎、鼻炎、气管炎。小儿的免疫系统尚未发育完全，机体免疫力、抵抗力